NEW YORK, NY / ACCESSWIRE / February 7, 2023 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Twist Bioscience Corporation (NASDAQ:TWST)
This lawsuit is on behalf of a class of all persons and entities who purchased or otherwise acquired Twist common stock between December 13, 2019 and November 14, 2022, inclusive.
A class action has commenced on behalf of certain shareholders in Twist Bioscience Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) as alleged in the November 15, 2022 report by Scorpion Capital, defendants overstated the commercial viability of Twist's synthetic DNA manufacturing technology; and 2) at the same time, defendants were engaging in accounting fraud and using unsustainable pricing to inflate the Company's true financial condition and prospects.
Shareholders may find more information at https://securitiesclasslaw.com/securities/twist-bioscience-corporation-loss-submission-form/?id=36329&from=1
Daktronics, Inc. (NASDAQ:DAKT)
Investors Affected : March 10, 2022 - December 6, 2022
A class action has commenced on behalf of certain shareholders in Daktronics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing challenges that increased costs, including supply chain disruptions, that impacted Daktronics' ability to fund inventory levels and operations; (2) as a result, it was probable that some portion of the Company's deferred tax assets would not be realized; (3) as a result, Daktronics was reasonably likely to record a material valuation allowance to its deferred tax assets; (4) there were material weaknesses in the Company's internal controls over financial reporting related to income taxes; (5) the foregoing presented liquidity concerns and there was substantial doubt as to the Company's ability to continue as a going concern; and (6) as a result of the foregoing, defendant's positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/daktronics-inc-loss-submission-form/?id=36329&from=1
Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ:IVVD)
This lawsuit is on behalf of all purchasers of Adagio common stock between November 29, 2021 and December 14, 2021, both dates inclusive.
A class action has commenced on behalf of certain shareholders in Invivyd, Inc f/k/a Adagio Therapeutics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (b) defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (c) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.
Shareholders may find more information at https://securitiesclasslaw.com/securities/invivyd-inc-f-k-a-adagio-therapeutics-inc-loss-submission-form/?id=36329&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm